Metropolis Healthcare Ltd

Metropolis Healthcare Q1 FY26: 23% Revenue Growth & Strategic Expansion 🚀

- Expanding basic radiology services (X-ray, sonography, ECG) across 20 locations, with further scaling planned.

- Added 80 new collection centers in Q1, targeting 400+ this year, focusing on Tier-2 and Tier-3 towns.

- Investing in AI-led diagnostics, decentralized point-of-care testing, and GLP-1 therapies in metabolic health.

- Building a center of excellence in oncology diagnostics (genomics, histopathology, molecular oncology).

- Smooth integration of 3 acquisitions (Core Diagnostics, DAPIC Dehradun, Scientific Pathology Agra) with expected lab and procurement synergies.

- Shift from low-margin government contracts to higher-margin B2C and specialty B2B segments.

- Competitive pressure eases as health tech players reduce discount-led growth.

- Q1 FY26 revenue growth: 23% (13.2% organic), driven by volumes and improved realizations.

- B2C segment contributed 59% of organic revenue, growing 16% YoY; B2B grew 10%.

- TruHealth preventive checkups contributed 18% of revenue, up 22% YoY.

- Organic EBITDA margin: 24.7%; PAT grew 21.2% YoY.

- Core Diagnostics now has low single-digit EBITDA margin (up from break-even in Q4 FY25).

- Acquired Ambika Diagnostics (Kolhapur) for ₹17 crores, expected to be EBITDA-accretive immediately (synergies boosting EBITDA to ₹3.4 crores).

- Refinanced Core Diagnostics' ₹12 crores loan in July at better rates, expecting improved PAT in Q2.